

Available online at www.sciencedirect.com

SciVerse ScienceDirect

journal homepage: <http://www.kjms-online.com>

ORIGINAL ARTICLE

Isocitrate dehydrogenase mutation hot spots in acute lymphoblastic leukemia and oral cancer

Jen-Yang Tang^{a,b,c}, Chun-Chi Chang^{d,e}, Pei-Chin Lin^{d,f}, Jan-Gowth Chang^{c,d,f,g,h,*}^a Faculty of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan^b Department of Radiation Oncology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan^c Cancer Center, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan^d Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan^e Division of Chest Medicine, Department of Internal Medicine, Changhua Christian Hospital, Changhua, Taiwan^f Division of Hematology and Oncology, Department of Pediatrics, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan^g Center of Excellence for Environmental Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan^h Department of Laboratory Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan

Received 14 March 2011; accepted 31 August 2011

Available online 20 January 2012

KEYWORDS

HRM;
IDH;
Leukemia;
Mutation;
Oral cancer

Abstract Isocitrate dehydrogenase (IDH) encodes a nicotinamide adenine dinucleotide phosphate+-dependent enzyme for oxidative decarboxylation of isocitrate and has an essential role in the tricarboxylic acid cycle. Mutations of IDH1 and IDH2 have been identified in patients with glioma, leukemia, and other cancers. However, the incidence of IDH mutations in acute myeloid leukemia in Taiwan is much lower than that reported in Western countries. The reason for the difference is unknown and its clinical implications remain unclear. Acute lymphoblastic leukemia (ALL) is a heterogenous hematopoietic malignancy. Oral squamous cell carcinoma (OSCC) results from chronic carcinogen exposures and is highly prevalent in trucking workers, especially in southern Taiwan. Subtypes of both diseases require specific treatments, and molecular markers for developing tailored treatments are limited. High-resolution melting (HRM) analysis is now a widely used methodology for rapid, accurate, and low-cost mutation scanning. In this study, 90 adults with OSC and 31 children with ALL were scanned by HRM analysis for IDH1 and IDH2 mutation hot spots. In ALL, the allele frequency was 3.23% in both IDH1 and IDH2. In OSCC, the allele frequency was 2.22% in IDH2. A synonymous mutation over pG313 (c.939A > G) of IDH2 was found in both pediatric ALL and adult OSCC. Therefore, we concluded that mutations of IDH are uncommon in ALL and OSCC and are apparently not a major consideration when selecting treatment modalities. Copyright © 2012, Elsevier Taiwan LLC. All rights reserved.

* Corresponding author. Department of Laboratory Medicine, Kaohsiung Medical University Hospital, 100 Shih-Chuan 1st Road, Kaohsiung, Taiwan.

E-mail address: jgchang@ms.kmuh.org.tw (J.-G. Chang).

Introduction

Isocitrate dehydrogenase (IDH) encodes a nicotinamide adenine dinucleotide phosphate (NADP)⁺-dependent enzyme for oxidative decarboxylation of isocitrate and produces 2-oxoglutarate and carbon dioxide in the tricarboxylic acid cycle. The recent discovery of somatic heterozygous mutations of IDH in glioblastoma is considered a major advance in oncology [1,2]. Mutations of IDH impair the ability to catalyze the conversion of isocitrate to α -ketoglutarate (α -KG), which decreases conversion of α -KG to the metabolite D2-hydroxyglutarate. Of the three IDH isoforms (IDH1, IDH2, and IDH3), two isoforms (IDH1 and IDH2) are associated with brain tumors [3–10], acute myeloid leukemia (AML) [11–15], myelodysplastic syndromes [16,17], prostate cancer [9], acute lymphoblastic leukemia (ALL) B [9], paraganglioma [18], thyroid cancer [19], and colorectal cancer [3,20]. Like tumor suppressors, heterozygous missense mutations of IDH1 residues act in a dominant negative fashion [18].

Most studies agree that mutational status in IDH1 and IDH2 is associated with poorer prognosis [11,21,22], while some studies report no correlations [12,23]. In low-grade glioma, however, IDH has a higher incidence of mutations [5,24], i.e., 68% in diffuse astrocytoma, 69% in oligodendroglioma, and 78% in oligoastrocytoma [24]. Grade IV secondary glioblastoma (GBM) also has a high incidence of IDH mutations (88%). Some evidence indicates that the IDH mutation is an early indicator of oncogenesis in secondary GBM [2].

Invasive oral squamous cell carcinoma (OSCC) accounts for most malignant disorders of the oral cavity. Histologic grading has limited value for predicting treatment outcomes. Despite recent advances in surgical, radiotherapy, and chemotherapy treatment protocols, the long-term survival of patients with OSCC has not substantially improved, and responses to different treatment modalities are difficult to predict [25]. Since OSCC apparently develops during several steps in the process of carcinogenesis after chronic carcinogen exposure, tailored treatments based on specific markers are needed [25,26]. Since many molecular markers have already been proposed e.g., p53, epidermal growth factor receptor, c-erbB2, c-Jun, Ki67, telomerase, cyclooxygenase-1 and -2, vascular endothelial growth factor, [26,27], this study investigated whether IDH has a role in the development of OSCC.

AML is a hematopoietic malignancy characterized by failure of the myeloid precursors to mature. Because AML is a heterogeneous disease, special therapeutic considerations are needed for its varied phenotypes. In addition to morphology and karyotype, World Health Organization classifications of molecular markers, such as genetic mutations of nucleophosmin, FMS-related tyrosine kinase, and CCAAT/enhancer-binding protein alpha, must be considered when selecting treatment strategies. ALL is also a heterogeneous disease comprising multiple subtypes with different genetic alterations and varied treatment responses [28].

Whole genome sequencing performed in searches for new molecular markers of AML have revealed arginine (R132) mutations in IDH1 [29,30]. A study of patients who have AML with a normal cytogenetic status found that 16% had mutated IDH1 [30]. Studies by different research

groups have also confirmed significant recurrence in IDH1 [11–15] and IDH2 mutations [13,16,21].

However, a recent National Taiwan University Hospital (NTUH) study of 493 patients with AML revealed a much lower (5.5%) incidence of IDH mutation [31]. Although a possible explanation for this low occurrence rate may be the differences in species between Western and Eastern countries, the sensitivity of the current detection method is insufficient to confirm this theory. This study compared the clinical and biological features of IDH mutations in AML and in other cancers (i.e., oral cancer) that are highly prevalent in betel nut users in southern Taiwan. The IDH1 and IDH2 mutations of ALL and oral cancer were analyzed in patients treated in Kaohsiung Medical University Hospital (KMUH). Additionally, samples from four patients with AML were analyzed to compare the difference between the KMUH and NTUH groups.

ALL is another form of leukemia associated with high rates of immature lymphocytes. In southern Taiwan, oral cancer is common in construction workers and truck drivers who habitually chew betel nut. Instead of the direct sequencing method used to detect mutations in the NTUH study [31], this study applied high resolution melting (HRM) analysis, which has proven highly effective for detecting mutations [32,33], polymorphisms, and epigenetic differences [34], and it is rapidly becoming the standard mutation scanning methodology. The polymerase chain reaction (PCR) amplification and analysis were performed in a well by closed-tube method [32,33]. The values obtained by real-time PCR (LightCycler[®] 480, Roche Applied Science, USA) in the HRM analysis were evaluated for use in identifying hot spots of IDH1 and IDH2 gene mutations.

Methods

Patients

Ninety patients who were recently diagnosed with oral cancer at Kaohsiung Medical University Hospital and Changhua Christian Hospital were recruited. Mononuclear cells were obtained from four pediatric patients with AML and 35 with ALL in accordance with protocols approved by the Institutional Review Boards of the Kaohsiung Medical University and Changhua Christian Hospital. Of the 35 pediatric patients with ALL, four were excluded from the final statistical analysis due to insufficient DNA to complete both the IDH1 and IDH2 surveys.

Mononuclear cell samples from AML and ALL patients were centrifuged and stored at -80°C before use. Biopsy samples were obtained from the oral cancer patients during surgery and before systemic treatment or radiotherapy using a protocol approved by the Institutional Review Board at Kaohsiung Medical University. All tissue specimens were classified histopathologically as squamous cell carcinoma and stored immediately after resection in liquid nitrogen before DNA extraction.

Design and synthesis of PCR primers

The genomic region spanning the wild-type V71, G97, G123, and R132 of IDH1 at Exon 4 was amplified by PCR with sense

and antisense primers 5'-AACGACCAAGTCACCAAGGA, and 5'-GCCAATGACTTACTTGATCC, respectively. Exon 4 and Exon 7 of IDH2, where a single nucleotide polymorphism (SNP) is normally found at R140, R172, and V294, were amplified by upstream primers of 5'-GGGGTTCAAATTCTGGTTGA and 5'-GTCAGCCTTCTGCCCTCTC and downstream primers of 5'-CAGTGGATCCCCTCTCCAC and 5'-TCCAGCCAGAGAAGAC CAAC, respectively.

DNA extraction

Blood DNA was extracted by first drawing 8 mL of blood into a Vacutainer with ethylene diamine tetra-acetic acid anticoagulant. After mixing with red cell lysis buffer (1 mM NH_4HCO_3 , 115 mM NH_4Cl), cell pellets were collected by centrifuge at 4°C. The cell pellets were resuspended in white cell lysis buffer (100 mM Tris-Cl pH 7.6, 40 mM EDTA pH 8, 50 mM NaCl, 0.2% SDS (sodium dodecyl sulfate), 0.05% sodium azide). Protein precipitate solution (~6 M NaCl) was added and spun to collect supernatant. The supernatant was then mixed with 100% isopropanol and centrifuged. The DNA was obtained by resuspending the pellet in TE buffer.

Fresh tumor tissues were frozen and stored in liquid nitrogen before analysis. The DNA was collected by first washing 60–80 mg of tissue with PBS (phosphate buffered saline). The dissected tissue was resuspended in DNA buffer (1 M Tris pH 8.0, 0.5 M EDTA) and incubated overnight with proteinase K (10 mg/ml) and 10% SDS at 45°C overnight. The DNA was purified using standard procedures for phenol extraction and ethanol precipitation as described previously [35].

HRM analysis

The IDH1 and IDH2 mutations were identified by HRM analysis as described previously [32,33,36]. The LightCycler 480 High Resolution Melting Master kit (Reference 04909631001, Roche Diagnostics, USA) was used according to manufacturer instructions, and LightCycler 480 GeneScanning Software version 1.0 (Roche Diagnostics) was used for all data analysis. The PCR reactions were performed in duplicate in 20 μL final volume using the LightCycler 480 High-Resolution Melting Master 1X buffer, containing Taq polymerase, nucleotides, ResoLight dye, and 30 ng DNA. For detecting IDH mutations, primers and MgCl_2 were used at a concentration of 0.25 $\mu\text{mol/L}$ and 2.5 mmol/L.

A SYBR green I filter (533 nm) was used in the PCR program, which included an initial denaturation–activation step at 95°C for 10 minutes and then 45 cycles of the following program: denaturation at 95°C for 15 seconds, annealing at 60°C for 15 seconds and extension at 72°C for 15 seconds, fluorescence detection in single acquisition mode. The melting program included three steps: (1) denaturation at 95°C for 1 minute, (2) renaturation at 40°C for 1 minute, and (3) subsequent melting by continuous fluorescent reading from 60 to 90°C at a rate of 25 acquisitions/°C. The curve shape and peak height in each curve were checked to confirm good reproducibility.

Direct sequencing

After identifying SNPs based on HRM analysis and normalized and temperature-shifted melting curves, the samples were subjected to direct sequencing using the sense and antisense primers as described previously [32,33,35]. Sequencing was performed in the ABI Prism 310 Genetic Analyzer (Applied Biosystems, USA) according to the manufacturer instructions. After HRM analysis, the samples were purified with PCR-M™ for system clean up (VIOGEN, Sunnyvale, CA USA) and then directly sequenced. The sequence reaction was performed in a final volume of 10 μL , including 1 μL of the purified PCR product, 2.5 $\mu\text{mol/L}$ of one of the PCR primers, 2 μL of ABI PRISM terminator cycle sequencing kit version 3.1 (Applied Biosystems, USA) and 2 μL 5X sequence buffer. The sequencing programme started from 96°C for 1 minute and was followed by 25 cycles of the following PCR program: denaturation at 96°C for 10 seconds, annealing at 50°C for 5 seconds, and extension at 60°C for 4 minutes.

Results

This study recruited 90 adults with OSCC and 31 pediatric patients with ALL. Four pediatric with AML were also analyzed. The primers were designed to provide sufficient specificity within a range of sequences in which four IDH1 mutation hot spots (V71, G97, G123, and R132) and three IDH2 (R140, R172, and V294) have been reported (Fig. 3). The mutational screening included one IDH1 exon and two IDH2 exons, which included 866 codons. Normalized temperature-shifted data were clearly differentiated between the mutation and normal samples.

Four heterozygous changes were found in ALL samples. One (s.22) resided in bp 315 at Exon 4 of IDH1. Fig. 1A (upper panel) shows the melting profile of s.22. A single nucleotide polymorphism of C > T was confirmed by direct sequencing (Fig. 1A, lower panel). No mutations were found in Exon 4 of IDH2 after direct sequencing of the suspected s.35 (Fig. 1B, left panel). Two ALL (s.18, s.21) and two AML specimens (s.34, s.37) specimens showed heterozygous changes in Exon 7 of IDH2 (Fig. 1B, right panel). Direct sequencing confirmed the occurrence of the same SNP at bp (base pair) 939 (Fig. 1C). Although one base substitution was noted, the same protein was encoded, which indicated a synonymous mutation. The estimated allele frequency of ALL was 3.23% in both IDH1 and IDH2 (two of 62).

Finally, 90 oral cancer squamous cell carcinomas were screened. Fig. 2 shows the normalized and temperature shifted difference plots. No mutations were found within Exon 4 in either IDH1 (Fig. 2A) or IDH2 (Fig. 2B). No nucleotide polymorphism was found in o.12 after direct sequencing (sequence chromatogram not shown). In Exon 7 of IDH2, the melting curve showed differences in normalized temperature-shifted data between mutation and normal samples. The c.21, a previously recognized single nucleotide polymorphism in ALL, was used as a positive control and mixed with OSCC samples for analysis. The o.11 and o.128 showed similarly shifted curves (Fig. 2C). They harbored the same SNP (A > G) at codon 313, which indicated a synonymous change. After sequencing, comparison




Figure 1. Detection of SNP in ALL and AML by HRM analysis and confirmation by direct sequencing. Normalized and temperature shifted difference plots for IDH1 and IDH2 genes. A. Mutation screening over exon4 of IDH1. The DNA samples of leukemia carrying heterozygous variation were distinguished after grouping of different melting curves by shapes (arrowhead: wild-type and heterozygous). Direct sequencing over the range of codons of interests revealed a rapid base change in bp 315 from Cytosine to Thymine. B. Left panel: Mutation screening over exon4 of IDH2. After obtaining the melting profile of s.35, direct sequencing revealed no mutation. Right panel: Mutation screening over exon7 of IDH2. The melting profiles for s.18, s.21, s.34 and s.37 clearly distinguished A > G. C. Representative sequencing chromatograms of wild-type (left panel) and IDH2 mutations (right panel) spanning the codon 939. Nucleotide variation from Adenine to Guanine is visible (arrowhead).

of melting profiles of o.123 and o.84 revealed no mutations. The estimated allele frequency was 2.22% (two of 180).

Compared with data reported in the literature, the number of allele changes observed in this survey was lower than those reported in earlier studies. However, allele change in pG313 might be seen as a novel finding (Fig. 3). Possible explanations are differences in tumour genetics and the different age range of the population. Another possibility is that the IDH mutations of interest were beyond the range of hotspots investigated in this study.

Discussion

The importance of mutation screening increases as treatment options become available for cancers that have different phenotypes but similar pathology. The main concerns when selecting mutation detection techniques are cost, mutation type, sample source, detection sensitivity, detection specificity, and template quality. Some sequencing methods detect mutations by identifying individual nucleotides with stands that are complementary




Figure 2. Detection of SNP in oral cancer by HRM analysis and confirmation by direct sequencing. Normalized and temperature shifted difference plots for IDH1 and IDH2 genes. Panel A, direct sequencing of exon 4 of IDH1 showing no mutations. Panel B, further direct sequencing of suspected heterozygous melting profile of o.12 showing no mutations. However, no mutation was found. Panel C, HRM screening of o.11 and o.128 and c.21 from a previous ALL specimen showing heterozygous curve pattern apparently harboring the same nucleotide polymorphism. Direct sequencing revealed no nucleotides mutations in o.123 and o.84.




Figure 3. IDH mutation hot spots. Blue triangles indicate reported mutations at specific residues. Red triangles indicate SNPs discovered in this study.

strand to the DNA sample. Such methods include direct sequencing [37], pyrosequencing [38], nested sequencing [39], mutant-enriched sequencing [40], cold sequencing [41], and HRM analysis. Although direct sequencing is currently considered the gold standard for detecting DNA mutations, its drawbacks are its high cost and the need for high-quality templates. Prescreening can minimize the need for downstream sequencing. HRM analysis, however, is relatively fast and cost-effective for both gene scanning and SNP detection. This robust and highly sensitive method is currently the preferred method of mutation detection in most diagnostic laboratories [42]. However, inconsistent quantities of DNA inputs can cause curve deviation and false positive results [32]. Poor sample amplification can also produce aberrant melting curves [32]. Therefore, direct sequencing is recommended for additional confirmation of melting curves.

This study revealed similar single nucleotide polymorphisms in pG313 (c.939A > G) and pG105 (c.315C > T). The latter is also found in adult patients with AML [43] and in pediatric patients with Wilms tumor [44]. This observation confirms that HRM is a useful technique in clinical settings. However, no amino acid mutation occurs in this context since both the GGA and GGG codon polymorphism are indicators of glycine translation, which is considered a synonymous change. Therefore, the clinical relevance of this codon variation was not investigated further. Allele frequency in IDH2 is 2.22% in oral cancer and 3.23% in ALL. Allele frequency of IDH1 is 3.23% in ALL and no mutation hotspots are detectable in OSCC. Since the observed nucleotide polymorphism is the transition of GGC to GGT, both of which encode glycine, this base change is assumedly neutral.

The only silent mutation observed in the four AML specimens was over pG313 (c.939A > G) of IDH2. The allele frequency is 25% (two of eight). No nucleotide polymorphisms were identified in IDH1. However, this may have been due to the limited numbers of specimens analyzed. This synonymous change occurred in the same codon as that observed in the ALL patients in this study. The biologic implications are unclear. However, since the patients in both groups were pediatric, the base change could be an early indication of the oncogenesis of pediatric malignancies.

Oral cancer is believed to result from multiple processes involving many genetic alterations. The most common cause is believed to be exposure to carcinogens associated with chronic use of betel nuts, tobacco, and alcohol. Although demographic and phenotypic presentations are generally similar, responses to standard treatment vary widely. Current therapies are not tailored to specific

genotypes. The discovery of novel gain-of-function IDH mutations in GBM and AML in the current study has promising therapeutic considerations. However, further studies are needed to identify associations among IDH, oral cancer, and even ALL. To date, no IDH mutations of OSCC have been reported. Possible explanations for the lack of R132C mutations observed in this study are the very low incidence of this mutation (reportedly 1.7%) and the small number of samples screened in this study. In short, this study found that HRM is a cost-effective method of mutation screening and that IDH is not a reliable molecular marker of oral cancer or ALL.

Acknowledgment

This work was supported by a grant from the Department of Health, Executive Yuan, R.O.C. (Taiwan) (DOH100-TD-C-111-002).

References

- [1] Yen KE, Bittinger MA, Su SM, Fantin VR. Cancer-associated IDH mutations: biomarker and therapeutic opportunities. *Oncogene* 2010;29:6409–17.
- [2] Dang L, Jin S, Su SM. IDH mutations in glioma and acute myeloid leukemia. *Trends Mol Med* 2010;16:387–97.
- [3] Bleeker FE, Lamba S, Leenstra S, Troost D, Hulsebos T, Vandertop WP, et al. IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. *Hum Mutat* 2009;30:7–11.
- [4] Watanabe T, Nobusawa S, Kleihues P, Ohgaki H. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. *Am J Pathol* 2009;174:1149–53.
- [5] Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, et al. IDH1 and IDH2 mutations in gliomas. *N Engl J Med* 2009;360:765–73.
- [6] Hartmann C, Meyer J, Balss J, Capper D, Mueller W, Christians A, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. *Acta Neuropathol* 2009;118:469–74.
- [7] Gravendeel LA, Kloosterhof NK, Bralten LB, van Marion R, Dubbink HJ, Dinjens W, et al. Segregation of non-p.R132H mutations in IDH1 in distinct molecular subtypes of glioma. *Hum Mutat* 2010;31:E1186–99.
- [8] Capper D, Weissert S, Balss J, Habel A, Meyer J, Jager D, et al. Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. *Brain Pathol* 2010;20:245–54.
- [9] Kang MR, Kim MS, Oh JE, Kim YR, Song SY, Seo SI, et al. Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers. *Int J Cancer* 2009;125:353–5.
- [10] Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A. Analysis of the IDH1 codon 132 mutation in brain tumors. *Acta Neuropathol* 2008;116:597–602.
- [11] Wagner K, Damm F, Gohring G, Gorlich K, Heuser M, Schafer I, et al. Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor. *J Clin Oncol* 2010;28:2356–64.
- [12] Ho PA, Alonzo TA, Kopecky KJ, Miller KL, Kuhn J, Zeng R, et al. Molecular alterations of the IDH1 gene in AML: a Children's Oncology Group and Southwest Oncology Group study. *Leukemia* 2010;24:909–13.

- [13] Gross S, Cairns RA, Minden MD, Driggers EM, Bittinger MA, Jang HG, et al. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. *J Exp Med* 2010;207:339–44.
- [14] Ward PS, Patel J, Wise DR, Abdel-Wahab O, Bennett BD, Collier HA, et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. *Cancer Cell* 2010;17:225–34.
- [15] Andrusis M, Capper D, Luft T, Hartmann C, Zentgraf H, von Deimling A. Detection of isocitrate dehydrogenase 1 mutation R132H in myelodysplastic syndrome by mutation-specific antibody and direct sequencing. *Leuk Res* 2010;34:1091–3.
- [16] Kosmider O, Gelsi-Boyer V, Slama L, Dreyfus F, Beyne-Rauzy O, Quesnel B, et al. Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms. *Leukemia* 2010;24:1094–6.
- [17] Tefferi A, Lasho TL, Abdel-Wahab O, Guglielmelli P, Patel J, Caramazza D, et al. IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. *Leukemia* 2010;24:1302–9.
- [18] Gaal J, Burnichon N, Korpershoek E, Roncelin I, Bertherat J, Plouin PF, et al. Isocitrate dehydrogenase mutations are rare in pheochromocytomas and paragangliomas. *J Clin Endocrinol Metab* 2010;95:1274–8.
- [19] Murugan AK, Bojdani E, Xing M. Identification and functional characterization of isocitrate dehydrogenase 1 (IDH1) mutations in thyroid cancer. *Biochem Biophys Res Commun* 2010;393:555–9.
- [20] Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, et al. The consensus coding sequences of human breast and colorectal cancers. *Science* 2006;314:268–74.
- [21] Marcucci G, Maharry K, Wu YZ, Radmacher MD, Mrozek K, Margeson D, et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. *J Clin Oncol* 2010;28:2348–55.
- [22] Paschka P, Schlenk RF, Gaidzik VI, Habdank M, Kronke J, Bullinger L, et al. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. *J Clin Oncol* 2010;28:3636–43.
- [23] Thol F, Damm F, Wagner K, Gohring G, Schlegelberger B, Hoelzer D, et al. Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia. *Blood* 2010;116:614–6.
- [24] Sonoda Y, Kumabe T, Nakamura T, Saito R, Kanamori M, Yamashita Y, et al. Analysis of IDH1 and IDH2 mutations in Japanese glioma patients. *Cancer Sci* 2009;100:1996–8.
- [25] Chang KP, Chang YT, Liao CT, Yen TC, Chen IH, Chang YL, et al. Prognostic cytokine markers in peripheral blood for oral cavity squamous cell carcinoma identified by multiplexed immunobead-based profiling. *Clin Chim Acta* 2011;412:980–7.
- [26] Chen YJ, Chang JT, Liao CT, Wang HM, Yen TC, Chiu CC, et al. Head and neck cancer in the betel quid chewing area: recent advances in molecular carcinogenesis. *Cancer Sci* 2008;99:1507–14.
- [27] Pitiyage G, Tilakaratne WM, Tavassoli M, Warnakulasuriya S. Molecular markers in oral epithelial dysplasia: review. *J Oral Pathol Med* 2009;38:737–52.
- [28] Collins-Underwood JR, Mullighan CG. Genomic profiling of high-risk acute lymphoblastic leukemia. *Leukemia* 2010;24:1676–85.
- [29] Ley TJ, Mardis ER, Ding L, Fulton B, McLellan MD, Chen K, et al. DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. *Nature* 2008;456:66–72.
- [30] Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, Chen K, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. *N Engl J Med* 2009;361:1058–666.
- [31] Chou WC, Hou HA, Chen CY, Tang JL, Yao M, Tsay W, et al. Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation. *Blood* 2010;115:2749–54.
- [32] Er TK, Liang WC, Chang JG, Jong YJ. High resolution melting analysis facilitates mutation screening of ETFDH gene: applications in riboflavin-responsive multiple acyl-CoA dehydrogenase deficiency. *Clin Chim Acta* 2010;411:690–9.
- [33] Lin CW, Er TK, Tsai FJ, Liu TC, Shin PY, Chang JG. Development of a high-resolution melting method for the screening of Wilson disease-related ATP7B gene mutations. *Clin Chim Acta* 2010;411:1223–31.
- [34] Wittwer CT, Reed GH, Gundry CN, Vandersteen JG, Pryor RJ. High-resolution genotyping by amplicon melting analysis using LCGreen. *Clin Chem* 2003;49:853–60.
- [35] Tajima K, Aminov RI, Nagamine T, Matsui H, Nakamura M, Benno Y. Diet-dependent shifts in the bacterial population of the rumen revealed with real-time PCR. *Appl Environ Microbiol* 2001;67:2766–74.
- [36] Montgomery JL, Sanford LN, Wittwer CT. High-resolution DNA melting analysis in clinical research and diagnostics. *Expert Rev Mol Diagn* 2010;10:219–40.
- [37] Sequist LV, Joshi VA, Janne PA, Bell DW, Fidias P, Lindeman NI, et al. Epidermal growth factor receptor mutation testing in the care of lung cancer patients. *Clin Cancer Res* 2006;12:4403s–8.
- [38] Daskalos A, Oleksiewicz U, Filia A, Nikolaidis G, Xinarianos G, Gosney JR, et al. UHRF1-mediated tumor suppressor gene inactivation in nonsmall cell lung cancer. *Cancer* 2011;117:1027–37.
- [39] Adkar-Purushothama CR, Maheshwar PK, Sano T, Janardhana GR. A sensitive and reliable RT-nested PCR assay for detection of Citrus tristeza virus from naturally infected citrus plants. *Curr Microbiol* 2011;62:1455–9.
- [40] Lin CH, Yeh KT, Chang YS, Hsu NC, Chang JG. Rapid detection of epidermal growth factor receptor mutations with multiplex PCR and primer extension in lung cancer. *J Biomed Sci* 2010;17:37.
- [41] Li J, Makrigiorgos GM. COLD-PCR: a new platform for highly improved mutation detection in cancer and genetic testing. *Biochem Soc Trans* 2009;37:427–32.
- [42] van der Stoep N, van Paridon CD, Janssens T, Krenkova P, Stamberгова A, Macek M, et al. Diagnostic guidelines for high-resolution melting curve (HRM) analysis: an interlaboratory validation of BRCA1 mutation scanning using the 96-well LightScanner. *Hum Mutat* 2009;30:899–909.
- [43] Zou Y, Zeng Y, Zhang DF, Zou SH, Cheng YF, Yao YG. IDH1 and IDH2 mutations are frequent in Chinese patients with acute myeloid leukemia but rare in other types of hematological disorders. *Biochem Biophys Res Commun* 2010;402:378–83.
- [44] Rakheja D, Mitui M, Boriack RL, DeBerardinis RJ. Isocitrate dehydrogenase 1/2 mutational analyses and 2-hydroxyglutarate measurements in Wilms tumors. *Pediatr Blood Cancer* 2011;56:379–83.